Introduction
============

Liver cancer (LC) is the second main reason of cancer related death worldwide of males, and is more common in developing countries. It is estimated that about 782,500 new LC cases and 745,500 deaths occurred worldwide during 2012, and more than half of them were from China [@B1]. However, the incidence of LC ranks third in China in cancers in males, and is becoming the third main reason of cancer related death in China in both males and females [@B2]. Due to the universal childhood HBV vaccination program, and improved hygiene and sanitation, the incidence of LC in China is showing a decreasing trend and mortality rate [@B1], [@B2]. However, the 5-year survival rate of LC is still generally low [@B3]. The histological type of most LCs is hepatocellular carcinoma (HCC) [@B4].

The rapid development of RNA-sequencing approach has led to the discovery of thousands of non-coding RNA (ncRNA) genes [@B5]. Non-coding RNAs, i.e. RNAs that cannot encode proteins, mainly include small RNAs and long-chain RNAs, and play extensive regulatory functions in many organisms such as bacteria, fungi, and mammals [@B6]. With the continuous development of RNA research, it has been found that mutations or the abnormal expression of non-coding RNAs are closely related to the occurrence of many diseases, and non-coding RNAs are also attracting more and more attention [@B7]. MicroRNAs (miRNAs) are small, short ncRNA molecules that regulate gene expression post-transcriptionally, whereas long non-coding RNAs (lncRNAs) are long ncRNAs that have also been identified as being involved in transcription regulation and the translation of target genes [@B7]. Numerous studies have reported that alterations of ncRNAs, including miRNAs and lncRNAs, are involved in tumorigenesis, progression, and metastasis of human cancers, as well as being therapeutic targets, and can also serve as diagnostic and prognostic biomarkers of cancer, including HCC [@B8]-[@B11]. LncRNAs or pseudogenes can serve as competing endogenous RNAs (ceRNAs), which can interact with miRNAs through miRNA response elements (MREs) to influence miRNA-induced targeted gene silencing [@B12]. The Cancer Genome Atlas (TCGA) is an open access database that includes 33 types of cancers and genome-wide sequencing datasets for more than 10,000 tumor samples, including HCC [@B13]. With such a comprehensive genome-wide sequencing dataset for HCC, how to deep-mine these data remains a huge challenge. With the proposed of ceRNA hypothesis, it is necessary to construct a HCC ceRNA network using the dysregulated genes of TCGA hepatocellular carcinoma database, and develop diagnostic and prognostic biomarkers for HCC. The goal of our current study was to identify a ceRNA network using these genes which are dysregulated between HCC tumors and the adjacent normal liver tissues from TCGA datasets, and to investigate underlying prognostic indicators for predicting overall survival (OS) in HCC patients.

Materials and Methods
=====================

TCGA data source
----------------

The expression of human RNA-sequencing (RNA-Seq; including lncRNAs and mRNAs) and miRNA-sequencing (miRNA-Seq) datasets were got from the TCGA website (<https://portal.gdc.cancer.gov/>, accessed November 5, 2017) [@B14], and the corresponding patients\' clinical parameters were obtain from the University of California, Santa Cruz Xena browser (UCSC Xena, <http://xena.ucsc.edu/>, accessed November 5, 2017). Patients with complete clinical prognostic parameters who received RNA-Seq or miRNA-Seq were included in the corresponding subsequent prognostic analysis. Patients who do not meet these criteria are respectively excluded from corresponding differentially expressed RNAs survival analysis. All of the above data were sourced from the TCGA database, and the use and acquisition of these data are according to TCGA data access policies and publication guidelines (<https://cancergenome.nih.gov/publications/publicationguidelines>). Therefore, the present study did not require additional ethics committee approval.

Identification of differentially expressed RNAs in HCC samples
--------------------------------------------------------------

All the HCC primary tumor and adjacent normal liver tissues of RNA-sequencing dataset were used for differentially expressed RNAs screening, and the recurrent tumor tissues were excluded from differential RNAs screening. The level 3 raw count data of RNA-Seq and miRNA-Seq datasets were both normalized by the *DESeq* [@B15] and*edgeR* [@B16] package in the R platform; each RNA with a mean value greater than 1 was included in the further analysis. The differentially expressed RNAs were screened by the *DESeq* and*edgeR* package using the R platform, and any RNAs overlapping between *DESeq* and*edgeR* were regarded as differentially expressed RNAs. Filter parameters of differentially expressed RNAs between HCC tumor and adjacent normal liver tissues were set as follows: a false discovery rate (FDR) \<0.05; and a \|log~2~ Fold Change (log~2~ FC)\| \> 2. A normalization dataset by *DESeq* was used for further analysis.

Competing endogenous RNA network construction and functional assessment
-----------------------------------------------------------------------

The ceRNA networks were constructed by differentially expressed genes (DEGs), differentially expressed miRNAs (DEMs), and differentially expressed lncRNAs (DELs) between HCC tumor and adjacent normal liver tissues. The lncRNA-miRNA interactions were identified by miRcode (<http://www.mircode.org/>, accessed November 5, 2017), which is a comprehensive searchable map of putative miRNA target sites across the complete GENCODE annotated transcriptome [@B17]. Whereas the potential target genes of DEMs were identified by TargetScan (<http://www.targetscan.org/>, accessed November 5, 2017) [@B18], miRDB (<http://www.mirdb.org/>, accessed November 5, 2017) [@B19] and miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>, accessed November 5, 2017) [@B20]; the target genes overlapping in the three online tools were considered as DEM-targeted genes. Then, the overlapping of these miRNA-mRNA and lncRNA-miRNA interactions with DEGs, DEMs and DELs, respectively, were included in further ceRNA network constructions. The flow chart of the ceRNA network construction is shown in **Figure [S1](#SM0){ref-type="supplementary-material"}**. To further understand the potential biological processes and pathways of these DEGs in ceRNA network, functional assessment was performed by the Database for Annotation, Visualization, and Integrated Discovery v6.8 (DAVID v6.8, <https://david.ncifcrf.gov/home.jsp>; accessed December 14, 2017), which consists of an integrated biological knowledge base and analytical tools aimed at systematically extracting biological meaning from large gene/protein lists [@B21], [@B22]. The directed acyclic graph of Gene Ontology (GO) terms was drawn by the Biological Networks Gene Ontology tool (BiNGO) in Cytoscape_v3.4.0 [@B23]. Gene-gene and protein-protein interactions of these DEGs in the ceRNA network were constructed by GeneMANIA (<http://www.genemania.org/>, accessed December 15, 2017) [@B24], [@B25] and the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, <https://string-db.org/>, accessed December 15, 2017) [@B26], [@B27], respectively.

Construction of the HCC-specific differentially expressed RNA-based prognostic signature
----------------------------------------------------------------------------------------

Further univariate Cox proportional hazards regression models were used to investigate the potential prognostic applications of these differentially expressed RNAs in the ceRNA network. Afterwards, these differentially expressed RNAs, which were significantly related to HCC overall survival (OS), were fitted into the optimal combination screening using a \"step\" function and used for further prognostic signature construction. These prognostic differentially expressed RNAs were included into the multivariate Cox regression model as dependent variables to calculate the relative contribution of these differentially expressed RNAs in a prognostic signature, and the weight of each differentially expressed RNA was assessed by the regression coefficient (β), which was generated from the multivariate Cox regression model. The HCC OS predicted risk score was calculated as follows: Risk score = Exp~RNA1~ × β~RNA1~ + Exp~RNA2~×β~RNA2~ + ... Exp~RNA~ × β~RNAn~ (Exp: expression level) [@B28]-[@B33]. The prediction accuracy of prognostic signature in HCC OS was evaluated through the *survivalROC* package in R platform. Furthermore, we also identified the underlying application of prognostic signature in distinguishing different clinical parameters. In order to test the potential application value of prognostic signature in HCC OS, we also implemented a comprehensive survival analysis to evaluate the prognostic signatures, including stratified survival analysis, nomogram, and joint effect survival analysis.

Gene set enrichment analysis
----------------------------

To understand the underlying mechanism between different risk scores, gene set enrichment analysis (GSEA, <http://software.broadinstitute.org/gsea/index.jsp>, accessed December 14, 2017) was employed to identify underlying mechanisms with different Molecular Signatures Database (MSigDB) gene sets, in which the c2 gene set (c2.all.v6.1.symbols.gmt) consisted of online pathway databases and the c5 gene set (c5.all.v6.1.symbols.gmt) consisted of genes annotated by Gene Ontology (GO) terms [@B34]-[@B36]. These enrichment results were at a significance level of *P*-value \<0.05 and FDR \<0.25 [@B34].

Statistical analysis
--------------------

Kaplan-Meier survival curves were applied to assess the prognosis between two groups with a log-rank test; those clinical parameters with a *P-*value \<0.05 were fitted into the multivariate Cox proportional hazards regression model as the adjustment variables. The comparison of gene expression levels between different subgroups was performed using the independent sample t-test. The diagnostic value of different RNAs was assessed by receiver operating characteristic (ROC) curves, with area under curve (AUC) and 95% confidence interval (CI) used to evaluate the accuracy of ROC curves. The volcano plots and heat maps were draw by the *ggplot2* package in the R platform. *P*-value \<0.05 was considered reached the statistically significant. All data statistical were conducted by SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) and R3.3.1.

Results
=======

Data source and differentially expressed RNAs screening
-------------------------------------------------------

For RNA-Seq dataset, we excluded 3 recurrent tumor tissues from DEG and DEL screening, then, a total of 371 HCC patients\' primary tumor and 50 adjacent normal liver tissues RNA-Seq dataset were used for DEG and DEL screening. Whereas, for miRNA-Seq dataset, we also excluded 3 recurrent tumor tissues from DEM screening, then, there were 372 HCC patients\' primary tumor and 50 adjacent normal liver tissues miRNA-Seq dataset were used for DEM screening. By performed the *DESeq* and *edgeR* in the R platform, a total of 938 genes (**Table [S1](#SM0){ref-type="supplementary-material"}**, **Figure [1](#F1){ref-type="fig"}A-C, Figure [S2](#SM0){ref-type="supplementary-material"}**), 38 miRNAs (**Table [S2](#SM0){ref-type="supplementary-material"}**, **Figure [1](#F1){ref-type="fig"}D-F, Figure [S3](#SM0){ref-type="supplementary-material"}**) and 555 lncRNAs (**Table [S3](#SM0){ref-type="supplementary-material"}**, **Figure [1](#F1){ref-type="fig"}G-I, Figure [S4](#SM0){ref-type="supplementary-material"}**) were identified as DEGs, DEMs and DELs, respectively. Then, a total of 370 HCC patients with complete clinical prognostic parameters, and received RNA-Seq were included in further DEGs and DELs survival analysis; the baseline information for these patients is summarized in **Table [S4](#SM0){ref-type="supplementary-material"}** [@B32]. A total of 371 HCC patients with complete clinical prognostic parameters, and received miRNA-Seq were included in further DEMs survival analysis; the baseline information for these patients is summarized in **Table [S5](#SM0){ref-type="supplementary-material"}** [@B30]. Survival analysis of clinical parameters suggests that tumor stage and radical resections were markedly correlate to HCC OS in the present study (both log-rank *P*\<0.05, **Table [S4](#SM0){ref-type="supplementary-material"} and S5**), and should be fitted into the multivariate Cox proportional hazards regression model as the adjustment variables.

Construction of the ceRNA network and functional assessment
-----------------------------------------------------------

After the miRcode analysis was used for identify the lncRNA-miRNA interactions between DEMs and DELs, we obtained 83 DEL-DEM interactions for further ceRNA network construction. Meanwhile, target genes of DEMs were also investigated by three online tools (TargetScan, miRDB and miRTarBase), and 16 DEM-DEG interactions were used for further ceRNA network construction. The ceRNA network was constructed based on these 99 interactions and is shown in **Figure [2](#F2){ref-type="fig"}**; this included 16 DEGs, 7 DEMs and 34 DELs. We also investigated the potential function of these DEGs in the ceRNA network using DAVID v6.8, and found that these DEGs were mainly involved in cell cycle, cell proliferation, and cell division biological processes (**Figure [3](#F3){ref-type="fig"}A**). Whereas these DEGs were mainly involved in the cell cycle, microRNAs in cancer signaling pathways (**Figure [3](#F3){ref-type="fig"}B**). The directed acyclic graph of these genes also showed that these DEGs were significantly enriched in cell cycle biological processes (**Figure [S5](#SM0){ref-type="supplementary-material"}**, highlighted in red). Network investigation by GeneMANIA and STRING suggest that these DEGs form a complex interaction with each other, in particular co-expression interactions (**Figure [S6](#SM0){ref-type="supplementary-material"}A-B**).

Construction of the HCC-specific differentially expressed RNAs-based prognostic signature
-----------------------------------------------------------------------------------------

To further identify the prognostic values of these genes in the ceRNA network, we first used an univariate Cox proportional hazards regression model to evaluate the relationship between these RNAs and HCC OS. There were 24 RNAs which were significantly associated with HCC OS, including nine DEGs, one DEM (**Figure [4](#F4){ref-type="fig"}A-C**), and 14 DELs (**Table [S6](#SM0){ref-type="supplementary-material"}**). Due to the miRNA-Seq and RNA-Seq dataset from TCGA possibly having a batch effect in data merge and as there was only one miRNA correlated to HCC OS in the present study, we only used nine DEGs and 14 DELs for further prognostic signature construction. Therefore, these 23 RNAs were next screening by *step* function to investigate the optimal combination for HCC OS prediction; a combination consisting of three DELs (AP002478.1, HTR2A-AS1, and ERVMER61-1; **Figure [5](#F5){ref-type="fig"}A-C**) and six DEGs (enhancer of zeste homolog 2 \[*EZH2*\], kinesin family member 23 \[*KIF23*\], chromobox 2 \[*CBX2*\], centrosomal protein 55 \[*CEP55*\], cell division cycle 25A \[*CDC25A*\], and claspin \[*CLSPN*\];**Figure [5](#F5){ref-type="fig"}D-I**) were considered the best combinations with the most significant *P*-value for HCC OS. Co-expression analysis revealed that these RNAs show a weak or moderate intensity of co-expression interactions, which were evaluated by the Pearson correlation coefficient (**Figure [S7](#SM0){ref-type="supplementary-material"}**). Afterwards, a multivariate Cox proportional hazards regression model was used for evaluate the relative weight for these genes in risk scores. The formula of the risk score was showed as follows: Risk score = exp~AP002478.1~ × (0.1163) + exp~HTR2A-AS1~ × (-0.1743) + exp~ERVMER61-1~ × (0.0839) + exp~EZH2~ × (0.3437) + exp~KIF23~ × (-0.2723) + exp~CBX2~ × (0.1396) + exp~CEP55~ × (0.2400) + exp~CDC25A~ × (-0.2002) + exp~CLSPN~ × (0.1522). Patients were grouped into two groups on the basis of the median value of risk score; those patients with a risk score less than the median value were defined as low risk, otherwise they were considered high risk. Survival analysis suggests that high risk patients were at a markedly increased risk of death in HCC (adjusted *P*\<0.0001, adjusted HR = 2.761, 95% CI = 1.838-4.147), and with a shorter OS (837*vs.* 2456 days for high risk *vs.* low risk, **Table [S4](#SM0){ref-type="supplementary-material"}**, **Figure [6](#F6){ref-type="fig"}A-B**). The accuracy of this prognostic signature in HCC long-term OS predictions was evaluated by a time-dependent ROC curve, and indicated that this prognostic signature showed a good performance in HCC long-term OS prediction with an AUC of 0.774, 0.730, 0.713, and 0.715 for 1-, 2-, 3-, and 5-year survival, respectively (**Figure [6](#F6){ref-type="fig"}C**). We also observed that the expression distribution of these nine RNAs were marked dysregulation between HCC tumors and adjacent normal liver tissues (**Figure [7](#F7){ref-type="fig"}A**), as well as between low risk and high risk groups\' tumor tissues (**Figure [7](#F7){ref-type="fig"}B**). The ROC curve confirmed that these dysregulated RNAs in the prognostic signature may have potential diagnostic value in distinguishing HCC tumors from adjacent normal liver tissues (**Figure [8](#F8){ref-type="fig"}A-I**). The prognostic signature constructed in our current study also show a good performance in predicting HCC clinical parameters (**Figure [9](#F9){ref-type="fig"}A-G**), such as tumor stage (*P*=0.01, AUC = 0.591, 95%CI = 0.521-0.661; **Figure [9](#F9){ref-type="fig"}A**), histological grade (*P*\<0.0001, AUC = 0.661, 95% CI = 0.604-0.718; **Figure [9](#F9){ref-type="fig"}B**), α-fetoprotein (AFP, *P*=0.048, AUC = 0.581, 95%CI = 0.504-0.659; **Figure [9](#F9){ref-type="fig"}C**), and radical resection (*P*=0.023, AUC = 0.610, 95%CI = 0.512-0.708; **Figure [9](#F9){ref-type="fig"}G**).

Comprehensive survival analysis of the differentially expressed RNA-based prognostic signature
----------------------------------------------------------------------------------------------

We further investigated the effect of this prognostic signature on HCC OS by using a stratified analysis after adjusting for tumor stage and radical resection in multivariate Cox proportional hazards regression model. As shown in **Figure [10](#F10){ref-type="fig"}A**, we observed that this prognostic signature notably increased the risk of death in all favorable and adverse strata, excluding in patients with Child-Pugh B/C stage, without hepatic fibrosis and radical resection, and female HCC patients. These results indicate that this prognostic signature may act as an independent prognostic risk factor for HCC prognosis. The nomogram also supported the stratified analysis results, and suggests that the risk score contributed the most risk points to HCC prognosis (range 0-100, **Figure [10](#F10){ref-type="fig"}B**) compared to other clinical parameters.

To further assess the combined effects of this prognostic signature and clinical features in HCC OS, joint effects survival analysis demonstrated that the combination of clinical features and prognostic signatures can significantly improve the value of these traditional clinical parameters in HCC OS prediction (all log-rank *P*\<0.0001, **Figure [11](#F11){ref-type="fig"}A-G**, **Table [1](#T1){ref-type="table"}**).

GSEA
----

To explore the mechanisms between different risk score groups, the GSEA approach was used for identify the potential biological processes and pathways between low risk and high risk HCC patients. GSEA analysis results of the c5 gene set reveal that the phenotype of high risk may through involved in cell cycle, cell division, DNA repair and replication biological processes (**Figure [12](#F12){ref-type="fig"}A-F, Table [S7](#SM0){ref-type="supplementary-material"}**), whereas the results of the c2 gene set suggest that the phenotype of high risk may through involved in cell cycle, DNA replication, PLK1, liver cancer proliferation and survival signaling pathways (**Figure [12](#F12){ref-type="fig"}G-L, Table [S8](#SM0){ref-type="supplementary-material"}**). These results are consistent with the functional enrichment results of DEGs in the ceRNA network by DAVID. It is suggested that the genes in this prognostic signature may cause differences between different risk phenotypes of HCC by affecting the basic state of cells, thus affecting the prognosis of HCC.

Discussion
==========

The ceRNA hypothesis was considered to be a novel regulatory mechanism that works through miRNA competition [@B12], [@B37]. With further study of ceRNA crosstalk, previous studies have shown that ceRNA genes were mediated by miRNA in complex ceRNA networks, as well as miRNA interacted with lncRNA [@B38]. Since TCGA has complete RNA and miRNA sequencing data, it is most appropriate to use this database for ceRNA and prognostic biomarker mining. Extensive studies have used part of the TCGA database to investigate the ceRNA network for multiple types of cancer, including HCC [@B39], lung cancer [@B40], [@B41], colon cancer [@B42], [@B43], bladder cancer [@B44], gastric cancer (GC) [@B45], papillary thyroid cancer [@B46] and pancreatic cancer (PC) [@B47]. A previous study by Zhang et al. identified a ceRNA network by using TCGA HCC dataset; however, the fold change of RNAs in their study was set as 3, which was not a conventional and strict criteria for differential expression RNAs [@B39]. Therefore, the results obtained in their study may not be reliable. The advantage of our current study is that we have set the differential expression RNAs as: \|log~2~ FC\|\>2 (\|FC\| \> 4), and identified a prognostic signature, which was based on RNAs from the ceRNA network, which may be a potential independent indicator for HCC OS.

The prognostic signature identified in the current study consisted of three DELs and six DEGs. Three DELs in the prognostic signature have not been reported in previous cancer studies, whereas among the six DEGs (*EZH2*, *KIF23*, *CBX2*, *CEP55*, *CDC25A*, and *CLSPN*), most have been reported in cancer prognosis and dysregulated in tumor tissue. Extensive studies have reported that the mRNA or protein expression of EZH2 was markedly increased in HCC tumor tissues [@B48]-[@B52], and that high expression of EZH2 can serve as a poor prognostic indicator in HCC [@B48], [@B52]. The results of EZH2 in our study are consistent with previous reports, and suggest that the mRNA expression of *EZH2* was significantly up-regulated in HCC tumor tissues and that high expression of *EZH2* was associated with unfavorable HCC OS. Cai et al. also reported that the immunohistochemistry of EZH2 may be a promising biomarker in distinguishing between HCC and non-malignant nodules in liver needle biopsies; our current study also confirmed that mRNA expression of *EZH2* also has a diagnostic value in distinguishing HCC from the adjacent normal liver tissues, which was consistent with the study of Cai et al [@B48]. Multiple studies have revealed that *EZH2* was the target gene for some non-encoding RNAs, and that altering the expression of them may affect the expression of *EZH2*, thereby affecting the HCC phenotype, such as cell proliferation and invasion [@B51], [@B53], [@B54]. Similar results can also be observed in other cancers, as the overexpression of EZH2 is significantly associated with aggressive tumor behavior and unfavorable prognosis in Merkel cell carcinoma [@B55], non-small cell lung cancer (NSCLC) [@B56], prostate cancer (PCa) [@B57], osteosarcoma [@B58], endometrial cancer [@B59], Luminal A Breast Cancer (BC) [@B60]. However, the opposite effect of EZH2 has also been reported in colorectal cancer (CRC), suggesting that the overexpression of EZH2 was significantly correlated with a better prognosis and serves as a useful prognostic biomarker for anti-EGFR therapy in CRC [@B61], [@B62].

The five remaining DEGs (*KIF23*, *CBX2*, *CEP55*, *CDC25A*, and *CLSPN*) in the prognostic signature were rarely reported in HCC. *KIF23*, which has been observed to be notably increased in tumor tissues and the high expression of *KIF23* was correlated with unfavorable prognosis in patients with glioma [@B63], [@B64], malignant pleural mesothelioma [@B65], lung cancer [@B66] and PC [@B67]. Functional experiments demonstrated that the knockdown of *KIF23* expression can suppress the proliferation of glioma cells*in vitro* [@B63]. The results of *KIF23* in HCC in the current study are also consistent with previous studies; furthermore, we also investigated the diagnostic value of *KIF23* in HCC and suggested that the mRNA expression of *KIF23* shows a good ability to distinguish between HCC tumors and adjacent normal liver tissue. A similar effect also can be observed in *CBX2*; Clermont et al. reported that *CBX2* may play an oncogenic role in human neoplasms, and that the high expression of *CBX2* was markedly correlated with an unfavorable OS in BC [@B68]. Another independent study by Liang et al. also validated these results in another independent cohort [@B69]. Clermont et al. also observed that *CBX2* was recurrently up-regulated in metastatic PCa, and that patients with up-regulated expression of *CBX2* had a significantly lower disease-free survival [@B70].

A previous HCC bioinformatics analysis study based on the Gene Expression Omnibus database showed that *CEP55* was up-regulated in HCC tumor tissue, and that the increased expression of *CEP55* was correlated with a short OS and DFS [@B71], which were consistent with the results we obtained in current study. The overexpression of *CEP55* in tumor tissue has also been reported in PC [@B72], head and neck squamous cell carcinoma [@B73], epithelial ovarian carcinoma [@B74], GC [@B75], and BC [@B76]. In addition, *CEP55* also served as a poor prognostic indicator in PC [@B72] and epithelial ovarian carcinoma [@B74]. Functional investigation suggests that *CEP55* may act as an oncogene in cancers, and that the overexpression of *CEP55* can promote cancer cell proliferation or invasion in PC [@B72], epithelial ovarian carcinoma [@B74], GC [@B75], and BC [@B76].

A study by Xu et al. demonstrated that *CDC25A* was up-regulated in HCC tumor tissue, and showed lower expression in liver cirrhosis and chronic hepatitis tissues [@B77]. The high expression of *CDC25A* was correlated with a markedly increased risk of HCC death and early recurrence, and could be serve as an independent prognostic indicator for HCC [@B77], in another words, the overexpression of *CDC25A* correlates with a more aggressive disease progression and an unfavorable prognosis in patients with HCC [@B78], which was in good agreement of our results. Furthermore, Wang et al. also reported that elevated CDC25A expression markedly associated with HCC tumor-node-metastasis staging, as well as venous invasion [@B79]. Functional exploration confirmed that the antagonism of *CDC25A* could inhibit the growth and invasion of HCC cells via cell cycle arrest at G0**-**G1 and suppress MT3**-**MMP expression, acting as an oncogene in HCC [@B80]. Similar carcinogenesis functions have also been observed in human gliomas [@B81]. However, functional investigation of another DEG,*CLSPN*, in the prognostic signature, demonstrated that *CLSPN* expression was markedly increased in cancer cell lines and tumor tissues, with a significant positive correlation with Ki-67, and may be a potential proliferation marker for cancers [@B82].

By analyzing the function of DEGs in the ceRNA network via DAVID, and GSEA analysis between low- and high-risk groups, we found that these DEGs were relevant to cell cycle biological processes and pathways; GSEA analysis also revealed that high-risk scores were also significantly enriched in cell cycle progression. We infer that this ceRNA network and prognostic signature may influence cell homeostasis by regulating the cell cycle, thereby affecting cell proliferation and the invasion of liver cancer, which affects disease progression and prognosis. By reviewing the relative literature, we found that DEGs such as CCNB1 and CCNE1, play key roles in the control of cell cycle phase transition in hepatocytes and HCC cells [@B83]-[@B85]. Among the six DEGs in the prognostic signature, most were also involved in cell cycle processes. The tumor suppressor miR-101 dramatically repressed cell cycle progression *in vitro* through directly targeting *EZH2* in HCC [@B86], and some non-coding RNAs also take part in HCC cell cycle regulation via targeting *CDC25A* [@B87], [@B88]. Chang et al. demonstrated that CEP55 protein levels are regulated through a p53-Plk1-CEP55 axis, which is related to the mechanisms of p53-mediated repression in cell cycle processes [@B89]. Also, p53-dependent mechanisms have been reported in KIF23, and may be a principal mechanism for G2/M cell cycle arrest in cancer cells mediated by p53 [@B90]. The function of CLSPN plays a role in controlling the rates of DNA replication during the normal cell cycle, and is required for normal rates of global replication fork progression [@B91].

Due to the existence of a moderate intensity co-expression relationship between the above six DEGs, they are similar in terms of gene function, tumorigenesis and prognosis value. In the present study, these DEGs were notably increased in HCC tumor tissue, and the reduced expression of these genes predicted a better survival in patients with HCC, consistent with the previous studies of cancers. As well as in terms of genes function, previous studies reported that these DEGs were involved in cell cycle processes, and our enrichment analysis also indicated that these DEGs were relevant to the cell cycle in HCC.

In the present study, there were some limitations that need to be acknowledged. First, since all of the data in the current study were from TCGA, and the clinical information is incomplete, adjustment of the prognostic signature in the multivariate Cox proportional hazards regression model was not comprehensive, and cannot fully take into account these factors, which may affect HCC prognosis, but were not provided in the TCGA website. Second, as other public databases cannot provide a complete RNA-seq and miRNA-seq dataset in the same cohort of patients at the same time, and these datasets are not suitable to be used for ceRNA network construction; therefore, an additional verification cohort is needed to validate our results in future study.

Despite these limitations, in the present study we identified a large number of DEGs, DEMs and DELs between HCC primary tumor and adjacent normal liver tissues. Also, a ceRNA network of HCC was constructed based on these dysregulated RNAs via the bioinformatics approach, and a prognostic signature for HCC OS was developed. These findings may help to advance the understanding of dysregulated RNAs participating in the hepatocarcinogenesis, development, and prognosis of HCC, and will provide the foundation to develop novel clinical diagnostic and therapeutic biomarkers.

Conclusions
===========

Through the comprehensive analysis of HCC RNA-Seq and miRNA-Seq datasets from TCGA, we constructed a ceRNA network based on 16 DEGs, 7 DEMs and 34 DELs, which may play a critical role in hepatocarcinogenesis. Furthermore, we also investigated a prognostic signature, which included three DELs and six DEGs, as a potential outcome predictor for HCC patients based on the ceRNA network. The potential mechanisms of this prognostic signature may be involved in the regulation of the cells\' basic status, thus may affecting the clinical outcome of HCC. However, future functional investigations are still required to verify the mechanisms underlying the roles of these genes in HCC prognosis.
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![Expression distribution of 9 prognostic signature RNAs between HCC tumor and adjacent normal liver tissues, and low- and high-risk groups. **Notes**: (A) Scatter plot of 9 prognostic signature RNAs expression level between HCC tumor and adjacent normal liver tissues. (B) Scatter plot of 9 prognostic signature RNAs expression level between low- and high-risk groups.](jcav10p3267g007){#F7}

![Diagnosis ROC curve of 9 prognostic signature RNAs between HCC tumor and adjacent normal liver tissues. **Notes**: The order of ROC curves of 9 prognostic signature RNAs were as follow: (A) HTR2A-AS1, (B) AP002478.1, (C) ERVMER61-1, (D) EZH2, (E) KIF23, (F) CBX2, (G) CEP55, (H) CDC25A, (I) CLSPN.](jcav10p3267g008){#F8}

![The predictive values of the risk score for the HCC clinical features. **Notes**: ROC curve of risk score for clinical features: (A) tumor stage, (B) histological grade, (C) serum AFP, (D) MVI, (E) Child-Pugh score. (F) ishak fibrosis score, (G) radical resection.](jcav10p3267g009){#F9}

![The relationship between risk score and clinical features. **Notes**: (A) Stratified analysis results of risk score in HCC OS. (B) Nomogram for predicting the 1-,3- and 5-year event (death) with risk score and clinical features.](jcav10p3267g010){#F10}

![Joint effects survival analysis of OS stratified by risk score and HCC clinical features. **Notes**: Joint effects analysis stratified by risk score and following clinical features: (A) tumor stage, (B) histological grade, (C) serum AFP, (D) MVI, (E) Child-Pugh score. (F) ishak fibrosis score, (G) radical resection.](jcav10p3267g011){#F11}

![GSEA results of c5 and c2 reference gene sets in high-risk groups. **Notes**: GSEA results for c5 reference gene sets (A**-**F) and c2 reference gene sets (G**-**L).](jcav10p3267g012){#F12}

###### 

Joint effects survival analysis of clinical features and the prognostic signature with OS in HCC patients

  Group   Risk Score      Variables                         Events/total(n=370)   MST (days)   Crude HR (95% CI)     Crude *P*   Adjusted HR (95% CI)   Adjusted *P*^£^
  ------- --------------- --------------------------------- --------------------- ------------ --------------------- ----------- ---------------------- -----------------
                          **Tumor Stage ^c^**                                                                                                           
  A       **Low risk**    **Stage I**                       17/106                2532         1                                 1                      
  B       **Low risk**    **Stage II**                      7/34                  3258         1.273(0.527-3.075)    0.592       1.283(0.531-3.104)     0.58
  C       **Low risk**    **Stage III+IV**                  13/33                 1622         2.916(1.416-6.008)    0.004       2.894(1.405-5.936)     0.004
  D       **High risk**   **Stage I**                       25/65                 1372         3.473(1.872-6.442)    \<0.0001    3.446(1.857-6.393)     \<0.0001
  E       **High risk**   **Stage II**                      19/51                 1149         3.853(1.996-7.439)    \<0.0001    3.812(1.974-7.362)     \<0.0001
  F       **High risk**   **Stage III+IV**                  35/57                 419          6.419(3.577-11.520)   \<0.0001    5.839(3.211-10.617)    \<0.0001
                          **Histological Grade ^d^**                                                                                                    
  a       **Low risk**    **G1**                            10/39                 2131         1                                 1                      
  b       **Low risk**    **G2**                            25/97                 2456         1.045(0.501-2.177)    0.907       1.388(0.563-3.424)     0.476
  c       **Low risk**    **G3+G4**                         7/46                  NA           0.582(0.221-1.530)    0.272       0.830(0.278-2.476)     0.738
  d       **High risk**   **G1**                            8/16                  649          2.894(1.132-7.398)    0.026       3.186(1.034-9.819)     0.044
  e       **High risk**   **G2**                            35/80                 931          2.923(1.444-5.918)    0.003       3.209(1.318-7.813)     0.01
  f       **High risk**   **G3+G4**                         41/87                 757          2.814(1.406-5.633)    0.003       3.346(1.407-7.962)     0.006
                          **Serum AFP^e^**                                                                                                              
  I       **Low risk**    **≤400**                          25/118                2532         1                                 1                      
  II      **Low risk**    **\>400**                         4/26                  NA           0.651(0.226-1.873)    0.426       0.544(0.163-1.815)     0.322
  III     **High risk**   **≤400**                          37/95                 1271         2.735(1.641-4.558)    0.00011     2.702(1.578-4.628)     0.0003
  IV      **High risk**   **\>400**                         18/38                 931          2.630(1.427-4.850)    0.002       2.435(1.265-4.688)     0.008
                          **MVI**^**g**^                                                                                                                
  i       **Low risk**    **NO**                            39/168                2532         1                                 1                      
  ii      **Low risk**    **YES**                           5/15                  837          1.433(0.715-2.872)    0.311       1.165(0.523-2.5950     0.708
  iii     **High risk**   **NO**                            71/155                899          3.162(1.878-5.323)    \<0.0001    3.034(1.742-5.284)     \<0.0001
  iv      **High risk**   **YES**                           12/25                 1135         3.347(1.891-5.925)    \<0.0001    2.686(1.334-5.407)     0.006
                          **Child-Pugh score ^h^**                                                                                                      
  ①       **Low risk**    **A**                             24/118                3258         1                                 1                      
  ②       **Low risk**    **B+C**                           4/14                  1624         1.582(0.543-4.602)    0.4         1.636(0.560-4.776)     0.368
  ③       **High risk**   **A**                             35/98                 1372         2.713(1.607-4.582)    0.0002      2.635(1.542-4.5030     0.0004
  ④       **High risk**   **B+C**                           5/8                   394          5.261(1.998-13.856)   0.001       4.825(1.791-13.000)    0.002
                          **Ishak fibrosis score**^**b**^                                                                                               
  1       **Low risk**    **0**                             14/45                 2542         1                                 1                      
  2       **Low risk**    **1/2/3/4/5/6**                   10/72                 NA           0.510(0.224-1.162)    0.109       0.538(0.225-1.283)     0.162
  3       **High risk**   **0**                             16/29                 931          2.203(1.071-4.523)    0.032       1.903(0.893-4.054)     0.095
  4       **High risk**   **1/2/3/4/5/6**                   24/65                 1229         2.264(1.143-4.485)    0.019       2.640(1.288-5.411)     0.008
                          **Residual tumor**^**f**^                                                                                                     
  11      **Low risk**    **R0**                            24/115                2456         1                                 1                      
  22      **Low risk**    **R1+R2+RX**                      12/50                 3258         2.696(1.057-6.876)    0.038       2.579(0.904-7.355)     0.076
  33      **High risk**   **R0**                            36/91                 1005         3.075(2.074-4.558)    \<0.0001    2.982(1.946-4.570)     \<0.0001
  44      **High risk**   **R1+R2+RX**                      24/58                 1149         4.286(2.235-8.221)    \<0.0001    3.316(1.558-7.057)     0.002

Notes: ^b^ Information of ishak fibrosis score was unavailable in 159 patients; ^c^ Information of tumor stage was unavailable in 24 patients; ^d^ Information of histological grade was unavailable in 5 patients; ^e^ Information of serum AFP was unavailable in 93 patients; ^f^ Information of radical resection was unavailable in 7 patients; ^g^ Information of micro vascular invasion was unavailable in 56 patients; ^h^ Information of Child-Pugh score was unavailable in 132 patients; £Adjusted for tumor stage and radical resection.

**Abbreviations:** OS, overall survival; HCC, hepatocellular carcinoma; MST, median survival time; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; MVI, micro vascular invasion.
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